Tarlatamab's role in SCLC

WCLC 2026: Lung cancer research highlights

Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC

Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC

Using artificial intelligence to improve lung cancer screening and risk prediction

Subcutaneous tarlatamab shows encouraging efficacy in previously treated extensive-stage SCLC

Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma

Functional dependence predicts poorer survival in adults aged 80 and over with NSCLC

Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC

Adjuvant osimertinib delivers sustained long term survival benefit in EGFR mutated NSCLC

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Challenges in doing clinical research in the LATAM region